MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development
Portfolio Pulse from
MIRA Pharmaceuticals has submitted an IND application to the FDA for Ketamir-2, a novel oral ketamine analog for treating neuropathic pain. This submission is a significant milestone in the company's pipeline development.
December 19, 2024 | 2:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MIRA Pharmaceuticals has submitted an IND application to the FDA for Ketamir-2, a novel oral ketamine analog for treating neuropathic pain. This submission is a significant milestone in the company's pipeline development.
The submission of an IND application to the FDA is a critical step for MIRA Pharmaceuticals as it advances its lead drug candidate, Ketamir-2. This development could positively impact the company's stock price as it demonstrates progress in their drug pipeline and commitment to meeting milestones.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100